Obstructive lung disease is a category of respiratory disease characterized by airway
obstruction. Many obstructive diseases of the lung manifest due to the narrowing of bronchi
which often cause excessive contraction of smooth muscles. The major types of obstructive
lung disease include asthma, bronchiectasis, bronchitis and chronic obstructive pulmonary
disease (COPD). Increase in prevalence of COPD and asthma patients, rising geriatric
population, increase in pipeline products, growing government and non-government
initiatives for spreading awareness are the major factors driving the growth of the Global
Obstructive Lung Diseases Market.
The Global Obstructive Lung Disease Market is expected to grow at a CAGR of
approximately 8.5% during the forecast period 2017-2023.
As per the Global Burden of Disease study, it is estimated that chronic obstructive
pulmonary disease caused 3.2 million deaths globally in 2015. Disease burden due to COPD
was the highest in India, Nepal, Papua New Guinea, and Lesotho. COPD manifests itself as
an occupational hazard in people working in agriculture, mining, plastics, and other
industries.
Governments across each country have implemented regulations for the production,
standardization, and utilization of COPD devices. These devices are divided into categories –
Class-I, Class-II, Class-III, and Class-IV, depending upon the level of risk associated.
However, stringent government regulatory requirement for the approval of asthma and
COPD drugs, side effects associated with the drug treatment, and patent expiry of drugs
restrict the market growth.
Key Players
The leading market players in the Asthma and COPD Drug focus to expand their business
operations in the emerging countries. The companies operating in the market have
consistently introduced innovative solutions to enhance their product portfolio. Product
approval and clinical trial are observed as the two prominent growth strategies adopted by
the key market players.
Some of key the players in the Global Obstructive Lung Disease Market are GlaxoSmithKline
(GSK) (U.K), Novartis AG (Switzerland), Merck & Co. Inc. (U.S), Abbott Laboratories (U.S),
Boehringer Ingelheim (Germany), AstraZeneca (U.K), Roche Holding AG (Switzerland), Teva
Pharmaceutical Industries (Israel), Vectura Group (U.K), Pfizer Inc. (U.S), Mylan (U.S.),
Aerovance Inc. (U.S.), Alkermes Inc. (U.S.), Almirall SA. (U.S.), Genentech Inc. (U.S.),
Sepracor, Inc. (U.S.), Skyepharma plc (U.S.).
Get Sample Copy at https://www.marketresearchfuture.com/sample_request/5367 .
Segmentation
The obstructive lung disease is segmented on the basis of disease type, product type, drug
class, route of administration and end-users.
On the basis of disease type, the market is segmented into asthma, bronchiectasis,
bronchitis and chronic obstructive pulmonary disease (COPD), and others
On the basis of product type market is segmented into inhalers, and nebulizers and others.
Inhalers are divided into Drug Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Soft
Mist Inhalers (SMIs) and others. Moreover the nebulizers are divided into compressor
nebulizers, ultrasonic nebulizers, and mesh nebulizers
On the basis of drug class, the market is segmented into combination drugs, leukotriene
antagonists (LTA), inhaled corticosteroids (ICS), anticholinergics, short acting beta agonists
(SABA), long acting beta agonists (LABA), and others. Furthermore, the Combination
products is divided into seretide/advair, symbicort, relvar/breo ellipta, flutiform, dulera, and
others. Leukotriene Antagonists (LTA) is divided into singulair and others. Inhaled
Corticosteroids (ICS) is divided into qvar, pulmicort, aerospan, flovent, and others.
Anticholinergics is divided into Spiriva and Others. Short Acting Beta Agonists (SABA) is
divided into proair, ventolin, and others.
On the basis of route of administration, market is segmented into oral, inhaler, intravenous,
subcutaneous, and others